EQT Fund Management S.a r.l. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001834239

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedTechnology Tilt how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025

Q3 2026 · 6 positions · Total reported value $947.44M · Top-10 concentration 100.0% · Updated 2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

Turnover: 16.7% · 1 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, EQT Fund Management S.a r.l. disclosed 6 equity positions with a combined reported value of $947.44M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Technology Tilt.

The largest disclosed positions as of Q3 2026 were WAY ($630.44M), PHVS ($108.63M), OCS ($64.92M). By sector, the heaviest allocations are Technology 66.5%, Health Care 29.0%. Versus the prior quarter, allocation shifted toward Technology (+7.3pp), Other (+4.5pp) and away from Health Care (-11.8pp).

Versus the prior quarter, EQT Fund Management S.a r.l. opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 16.7% of positions. The portfolio's overlap with the prior quarter was 83% of names.

The largest new positions opened in Q3 2026 were GRTX ($42.70M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • GRTX ELECTRA THERAPEUTICS INC · $42.70M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest EQT Fund Management S.a r.l. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

EQT Fund Management S.a r.l. files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 5 positions worth $862.62M in total. HoldingsHub carries 4 quarters of its filings (Q3 2025–Q2 2026).

Portfolio Structure

  • 5 positions · $862.62M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: WAY (WAYSTAR HLDG CORP) at 59.2%
  • Average position size: $172.52M

Sector Tilt

  • Information Technology 59.2%
  • Health Care 40.8%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 added
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased its allocation to WAYSTAR HLDG CORP (Technology) while reducing weights in Health Care names (PHVS, OCS, AGMB, EVMN), suggesting a tilt toward large-cap tech over biotech/healthcare, possibly driven by price appreciation rather than active buying. 2. Key moves: - Added: GRTX (ELECTRA THERAPEUTICS INC), 4.51% new position. - Reduced: No explicit reductions (action=Hold for all others; weight declines attributed to price effects). 3. Portfolio structure: Active (concentrated top-10 holdings), overweight Technology (66.54%) vs. Health Care (28.94%), high risk (single stock WAYSTAR at 66.54%). 4. Per-holding one-liner: - WAYSTAR HLDG CORP (Technology): Cloud-based healthcare software provider. - PHARVARIS N V (Health Care): Biopharma focused on respiratory diseases. - Oculis Holding AG (Health Care): Ophthalmology drug developer. - Agomab Therapeutics NV (Health Care): Autoimmune disease therapeutics. - EVOMMUNE INC (Health Care): Immuno-oncology biotech. - ELECTRA THERAPEUTICS INC (Health Care): Antibody discovery platform (unverified). 5. Style summary: Concentrated tech-biotech fund with a bullish tilt toward WAYSTAR, adding a small biotech position while passively rebalancing via price-driven weight shifts.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-13 03:39

Sector Allocation

Technology 66.5%
Health Care 29.0%
Other 4.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 24.88M $630.44M 66.54%
66.54%
Hold
2 3.42M $108.63M 11.46%
11.46%
Hold
3 6.95M $64.92M 6.85%
6.85%
Hold
4 5.14M $57.08M 6.02%
6.02%
Hold
5 5.29M $43.68M 4.61%
4.61%
Hold
6 3.80M $42.70M 4.51%
4.51%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 100% R 83% F1 91% (modelled on 2026-Q2; 5/10 hit)

Historical Backtest (3 quarters)

Avg precision 100% · recall 88% · F1 93% · avg rank error 1.2 · Top-10 turnover 6%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2026-Q1 100% 80% 89% WAY · OCS · PHVS · EVMN WAY · OCS · EVMN · PHVS · AGMB
2026-Q2 100% 100% 100% WAY · OCS · EVMN · PHVS · AGMB WAY · PHVS · OCS · EVMN · AGMB
2026-Q3 ★ 100% 83% 91% WAY · PHVS · OCS · EVMN · AGMB WAY · PHVS · OCS · AGMB · EVMN · GRTX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-11. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-11 Trading days30 Holdings1 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-11, and will update as prices arrive.

Portfolio return-37.03%Buy & hold
QQQ synthetic benchmark-11.15%Liquidity weighted
Excess return-25.88%vs benchmark
Barra annualised vol99.7%Model estimate
Realised vol91.3%Annualised in window
Weighted beta1.53Raw exposure
Factor / specific risk17% / 83%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)57.169.581.994.2106.610-0110-2211-11EQT Fund Management S.a r.l.QQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-37.03%Disclosed long book
QQQ synthetic benchmark-11.15%Liquidity-weighted constituents
Model universe, equal weight+2.07%Opportunity-cost reference
Excess return-25.88%Portfolio − benchmark
Arithmetic return sum-40.69%Difference vs compounded is the cross term
Weighted raw beta1.53Weighted holding betas
Realised volatility (annualised)91.32%Daily returns in window
Barra model volatility (annualised)99.72%Factor + specific
Factor share of variance17.3%Barra factors
Specific share of variance82.7%Stock residuals
Reported value$57.1M13F long US equity

2. Return attribution

The -40.69% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -2.00% -4.9%
Momentum & Growth 3 -0.75% -1.9%
Volatility & Tail Risk 7 -8.81% -21.6%
Industry 12 +9.47% 23.3%
Specific 1 -38.59% -94.8%
Return attribution (style + industry, %)-16.3-8.1+0.0+8.1+16.3Max Drawdown+0.41Amihud Illiquidity+0.83Turnover-1.15Short-term Reversal+1.85Growth-2.25Skewness-2.25Leverage (Downside Vol)+2.71Size+3.20Beta+3.35Kurtosis-3.81Mid Cap-5.12Residual Volatility+5.84Health Care+9.47Historical Volatility-15.06
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +9.47% +9.47% 23.3%
Residual Volatility Style +2.72 +2.15% +5.84% 14.3%
Beta Style +0.68 +4.92% +3.35% 8.2%
Size Style -1.66 -1.93% +3.20% 7.9%
Leverage (Downside Vol) Style -0.89 -3.05% +2.71% 6.7%
Short-term Reversal Style +1.65 +1.12% +1.85% 4.5%
Amihud Illiquidity Style +2.75 +0.30% +0.83% 2.0%
Max Drawdown Style -0.40 -1.01% +0.41% 1.0%
Non-linear Size Style +3.07 +0.07% +0.21% 0.5%
Momentum Style +0.11 -3.32% -0.35% -0.9%
Turnover Style +0.26 -4.35% -1.15% -2.8%
Growth Style -1.50 +1.50% -2.25% -5.5%
Skewness Style +0.47 -4.77% -2.25% -5.5%
Kurtosis Style -0.62 +6.17% -3.81% -9.4%
Mid Cap Style +2.67 -1.92% -5.12% -12.6%
Historical Volatility Style +1.53 -9.82% -15.06% -37.0%
Specific Specific — — -38.59% -94.8%

3. Risk attribution

Annualised volatility is 99.72%; factor risk explains 17.3% of variance and specific risk 82.7%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-89.4-44.7+0.0+44.7+89.4Skewness-0.35Kurtosis+0.33Growth+0.37Amihud Illiquidity+0.49Leverage (Downside Vol)+0.82Size+0.96Beta+1.41Non-linear Size+1.48Residual Volatility+1.64Mid Cap+2.59Health Care+3.51Historical Volatility+4.07Specific+82.74
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 82.7% +82.51% 82.5%
Historical Volatility Style +1.53 4.1% +4.06% 4.1%
Health Care Industry +1.00 3.5% +3.50% 3.5%
Mid Cap Style +2.67 2.6% +2.58% 2.6%
Residual Volatility Style +2.72 1.6% +1.64% 1.6%
Non-linear Size Style +3.07 1.5% +1.47% 1.5%
Beta Style +0.68 1.4% +1.41% 1.4%
Size Style -1.66 1.0% +0.96% 1.0%
Leverage (Downside Vol) Style -0.89 0.8% +0.82% 0.8%
Amihud Illiquidity Style +2.75 0.5% +0.49% 0.5%
Growth Style -1.50 0.4% +0.37% 0.4%
Kurtosis Style -0.62 0.3% +0.33% 0.3%
Skewness Style +0.47 -0.3% -0.35% -0.3%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.1-0.70.72.13.5Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.66 +2.10 -3.76
Non-linear Size +3.07 +1.68 +1.39
Mid Cap +2.67 +0.13 +2.54
Beta +0.68 +1.29 -0.61
Momentum +0.11 +0.72 -0.61
Short-term Reversal +1.66 -0.64 +2.30
Residual Volatility +2.72 -0.40 +3.12
Historical Volatility +1.53 +0.86 +0.67
Liquidity -0.17 +0.11 -0.28
Amihud Illiquidity +2.75 +1.16 +1.60
Turnover +0.26 +0.21 +0.06
Growth -1.50 +0.58 -2.08
Leverage (Downside Vol) -0.89 +0.14 -1.03
Skewness +0.47 +0.24 +0.23
Kurtosis -0.62 +0.21 -0.83
Max Drawdown -0.41 -0.08 -0.32

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -16.67% +4.61% +12.27% -12.27% +12.27%
Communication Services 0.0% 2.6% +0.00% -12.15% +0.05% +0.32% -0.32% +0.32%
Utilities 0.0% 0.8% +0.00% +10.14% -0.16% -0.08% +0.08% -0.08%
Consumer Staples 0.0% 0.8% +0.00% +15.33% -0.22% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.93% -1.44% -0.52% +0.52% -0.52%
Industrials 0.0% 11.1% +0.00% +7.87% -2.03% -0.87% +0.87% -0.87%
Health Care 100.0% 1.7% -37.03% +9.50% +19.56% -0.80% -45.72% -37.19%
Total +20.28% +10.15% -56.67% -26.24%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
AGMB Agomab Therapeutics NV Health Care 100.00% -37.03% -37.03% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 AGMB Health Care 100.00% -37.03% -37.03%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-11 (30 trading days), the reported portfolio returned -37.03%, versus -11.15% for the QQQ synthetic benchmark — an excess of -25.88%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +9.47%, Residual Volatility +5.84%, Beta +3.35%; the largest drags came from Historical Volatility -15.06%, Mid Cap -5.12%, Kurtosis -3.81%. Specific (stock-level) return contributed -38.59%.
  3. Risk attribution: Barra model volatility is 99.72% annualised; factor risk explains 17% of variance and specific risk 83%. The largest factor risk sources are Historical Volatility 4.1%, Health Care 3.5%, Mid Cap 2.6%.
  4. Style tilt: size -1.66, momentum +0.11, volatility +1.53, liquidity -0.17; the weighted raw beta is 1.53. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +20.28%, selection +10.15% and interaction -56.67%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did EQT Fund Management S.a r.l. buy in 2026-Q3?

In its 2026-Q3 13F filing, EQT Fund Management S.a r.l. reported 6 equity positions worth $947.44M in aggregate; its largest disclosed positions were WAY ($630.44M), PHVS ($108.63M), OCS ($64.92M).

How large is EQT Fund Management S.a r.l.'s portfolio?

EQT Fund Management S.a r.l. reported $947.44M of long equity holdings across 6 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is EQT Fund Management S.a r.l.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Technology Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eqt-fund-management-s-a-r-l/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →